Page last updated: 2024-11-03

probucol and Metabolic Syndrome

probucol has been researched along with Metabolic Syndrome in 1 studies

Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.

Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.

Research Excerpts

ExcerptRelevanceReference
" Previous results suggest that vascular dysfunction in OZR is associated with chronic reduction in vascular nitric-oxide (NO) bioavailability and chronic inflammation, both frequently associated with hypercholesterolemia."1.35Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome. ( Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA, 2009)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goodwill, AG1
Frisbee, SJ1
Stapleton, PA1
James, ME1
Frisbee, JC1

Other Studies

1 other study available for probucol and Metabolic Syndrome

ArticleYear
Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.
    Microcirculation (New York, N.Y. : 1994), 2009, Volume: 16, Issue:8

    Topics: Animals; Anticholesteremic Agents; Arterioles; Atorvastatin; Cytokines; Gemfibrozil; Heptanoic Acids

2009